Cancerna

RNA Processing For Anti-cancer Immunotherapy

About Us

CANCERNA’s general objective is the development and validation of novel RNA-based therapeutics targeting non-communicable diseases. The project is comprised of complementary activities to assess mode of action, including: in-vitro and in-vivo validation, bioinformatics, delivery, and safety.

In the past few years, new modalities of immunotherapy have opened a new era in the effectiveness of cancer treatment. This novel therapy modality has joined conventional cancer treatments such as surgery, chemotherapy, radiation, and targeted treatments as a pillar of cancer therapy. Cancers that were completely untreatable (such as metastatic melanoma) are showing dramatic positive responses to immunotherapy. Nevertheless, the huge promise of this treatment is diminished by the fact that only a limited percentage of patients are experiencing durable benefit from this new approach. For most patients,

About Us

CANCERNA’s general objective is the development and validation of novel RNA-based therapeutics targeting non-communicable diseases. The project is comprised of complementary activities to assess mode of action, including: in-vitro and in-vivo validation, bioinformatics, delivery, and safety.

In the past few years, new modalities of immunotherapy have opened a new era in the effectiveness of cancer treatment. This novel therapy modality has joined conventional cancer treatments such as surgery, chemotherapy, radiation, and targeted treatments as a pillar of cancer therapy. Cancers that were completely untreatable (such as metastatic melanoma) are showing dramatic positive responses to immunotherapy. Nevertheless, the huge promise of this treatment is diminished by the fact that only a limited percentage of patients are experiencing durable benefit from this new approach. For most patients,

Contact Info

consortium’s partners

The concept

CANCERNA is formed around the realization that cancers can be made immunogenic by ‘fixating’ defective/altered RNA products, to be translated into abnormal proteins that represent neo-antigens without leaving genomic footprints. Recently developed RNA oligonucleotides and mRNAs with improved chemistry and delivery will be fundamental to this task.
Skip to content